Investment Rating - The report assigns an "Outperform" rating for Qualcomm, indicating an expected relative return exceeding 10% over the next 12-18 months [21]. Core Insights - Qualcomm delivered solid 3Q25 results with revenue of $10.4 billion, up 10.4% YoY and down 4.3% QoQ, meeting market expectations [8][11]. - The company anticipates non-Apple QCT revenue to grow over 15% YoY for FY2025 and aims for combined Automotive and IoT revenue to reach $22 billion by FY2029 [8][9]. Summary by Sections Mobile Business - Mobile business revenue was $6.3 billion, reflecting a 7% YoY increase but a decline of 8.7% QoQ [2][8]. - The application of AI in smartphones is expanding, with significant growth in user engagement with AI features [2][8]. - Qualcomm has established a multi-year partnership with Xiaomi to support future flagship devices with Snapdragon 8 series platforms [2][8]. Automotive and IoT Growth - Automotive revenue reached $980 million, up 21% YoY and 2% QoQ, with strong traction for Snapdragon Digital Chassis solutions [3][9]. - IoT revenue was $1.68 billion, up 24% YoY and 6% QoQ, driven by demand for Snapdragon AR1 chips in AI smart glasses [3][9]. Acquisition Strategy - Qualcomm has agreed to acquire Alphawave IP Group plc, enhancing its capabilities in data centers and AI technologies, with the deal expected to close in 1QCY26 [4][10]. Future Guidance - For 4Q25, Qualcomm expects revenue between $10.1 billion and $11.1 billion, projecting a 12% YoY growth at the midpoint [5][11]. - Non-GAAP EPS is anticipated to be between $2.75 and $2.95, representing a 16% YoY increase [5][11].

Investment Rating - The report does not explicitly state an investment rating for ARM, but it provides insights into the company's performance and future expectations, indicating a generally positive outlook based on growth drivers in AI and custom chip solutions. Core Insights - ARM's FY1Q26 revenue was $1.05 billion, slightly below market consensus of $1.06 billion, with EPS at $0.35, in line with expectations. Royalty revenue increased by 25% YoY to $585 million, while License revenue decreased by 0.8% YoY to $468 million due to a strong base in FY1Q25 [1][6]. - The company is evolving towards full-end solutions to address increasing chip complexity and extended development cycles, with strong demand for Compute Subsystem (CSS) solutions, which have licensing fees twice that of Armv9 [2][7]. - ARM's custom chips are driving significant growth in cloud-based AI, with over 70,000 enterprises running AI workloads on Arm Neoverse chips, representing a 40% YoY increase. The company expects to capture nearly 50% market share among leading hyperscale customers this year [3][8]. - For 2Q26, ARM expects revenue between $1.01 billion and $1.11 billion, with a midpoint representing a 25% YoY increase. Non-GAAP EPS is projected to be between $0.29 and $0.37, with a median of $0.33, slightly below market expectations [9]. Summary by Sections Financial Performance - FY1Q26 revenue: $1.05 billion, slightly below consensus of $1.06 billion - EPS: $0.35, in line with expectations - Royalty revenue: $585 million, up 25% YoY - License revenue: $468 million, down 0.8% YoY [1][6] Business Strategy - ARM is transitioning to full-end solutions to tackle chip complexity and development cycles - Demand for CSS exceeds expectations, with licensing fees significantly higher than previous models - ARM supports chiplet development and aims to expand into complete solutions [2][7] AI and Market Outlook - Over 70,000 enterprises using Arm Neoverse chips for AI workloads, a 40% YoY increase - Expected market share among hyperscale customers to approach 50% - ARM's platform combines AI performance with energy efficiency, enhancing TCO [3][8] Future Guidance - 2Q26 revenue guidance: $1.01 billion to $1.11 billion, midpoint indicating 25% YoY growth - Non-GAAP EPS guidance: $0.29 to $0.37, median of $0.33, below market consensus [9]

Investment Rating - The report maintains an "Outperform" rating for multiple leading innovative drug companies and CXOs in the healthcare sector [2]. Core Insights - The report emphasizes a sustained positive outlook on the innovative drug industry and its supply chain, highlighting the importance of increasing allocations to leading companies in this space [4][6]. - The performance of the Hong Kong stock picks portfolio showed an average increase of 27.1% in July 2025, outperforming the Hang Seng Healthcare Index, which rose by 22.8% [5][9]. - Major business development (BD) and merger & acquisition (M&A) activities in the innovative drug sector are ongoing, with significant deals reported, indicating a robust market environment [6][35][36]. Summary by Sections Investment Focus - The report lists several companies with an "Outperform" rating, including 恒瑞医药 (Hengrui Pharmaceuticals), 迈瑞医疗 (Mindray), 药明康德 (WuXi AppTec), and others [2]. Performance Analysis - The July 2025 Hong Kong stock picks portfolio included companies like 信达生物 (Innovent Biologics) and 百济神州 (BeiGene), with top performers showing significant gains, such as 映恩生物 (DualityBio) at +48.0% [5][10]. - The healthcare sector in Hong Kong saw notable gains, with companies like 华检医疗 (IVD Medical) and 加科思-B (Jacobio Pharmaceuticals) leading the way [6][34]. Market Trends - The report highlights a recovery in the global innovative drug sector, with leading CXO firms like 药明合联 (WuXi XDC) and 药明康德 (WuXi AppTec) reporting strong earnings growth [7][37]. - Optimized centralized procurement policies and steady progress in innovative drug reimbursement are noted, with over 100 drugs applying for inclusion in the innovative drug reimbursement list [7][38][39]. Company-Specific Insights - 石药集团 (CSPC) and 中国生物制药 (Sino Biopharmaceutical) are newly added to the top picks, with strong potential in their respective innovative drug pipelines [4][32]. - The report discusses the promising clinical pipelines of companies like 三生制药 (3SBio) and 信达生物 (Innovent Biologics), indicating robust growth prospects [18][23].

Investment Rating - The report does not explicitly state an investment rating for Lam Research, but the strong performance and growth indicators suggest a positive outlook for the company. Core Insights - Lam Research delivered a strong performance in 4Q2025, with revenue reaching $5.17 billion, up approximately 9.5% quarter-over-quarter, and non-GAAP EPS hitting a record high of $1.33, significantly up from $1.04 in 3Q [1][7] - The company is experiencing robust growth momentum, with FY2025 revenue reaching $18.44 billion, a year-over-year increase of about 23.7% [1][7] - The balance sheet remains sound, with net accounts receivable of $3.228 billion and inventory of $4.463 billion [1][7] Summary by Sections Financial Performance - In 4Q, Lam Research's systems revenue was dominated by the foundry segment, accounting for 52% of total revenue, driven by AI-related transistor performance demands [3][9] - Non-volatile memory (NVM) contributed 27%, aligning with NAND customers converting capacity to ≥200 layers, while DRAM made up 14% [3][9] - The customer support business group generated $1.73 billion in 4Q revenue, maintaining stable performance with a 3% quarter-over-quarter increase [3][10] Market Trends and Technology - The company continues to make breakthroughs in critical technology areas, with significant momentum in Equipment Intelligence-enabled Dextro cobots and investments in GAA, advanced packaging, HBM, and NAND layer conversions [2][8] - The 2025 served available market (SAM) is expected to account for over 30% of wafer fabrication equipment (WFE) [2][8] - ALTUS Halo ALD Mo technology is rapidly being adopted, driving a threefold increase in metallization SAM per wafer [2][8] Outlook - Lam Research raised its 2025 WFE spending forecast to approximately $105 billion, primarily driven by increased domestic spending in China [4][11] - For 1Q2026, the company projects revenue of $5.2 billion ± $300 million, with a non-GAAP gross margin of 50.0% ± 1% [4][11] - Long-term, the company anticipates expanding its SAM to over 30% of WFE and capturing more than 50% of incremental SAM [4][11]

Investment Rating - The report maintains an "Outperform" rating for Hisense Home Appliances Group with a target price of RMB34.58, indicating an expected upside from the current price of RMB25.69 [2][6]. Core Insights - The company reported stable growth in revenue and net profit for the first half of 2025, achieving revenue of RMB49.34 billion (YoY +1.44%) and net profit of RMB2.08 billion (YoY +3.01%) [3][11]. - The overseas market continues to show strong performance, with overseas revenue reaching RMB20.45 billion, a growth of 12.3% YoY, driven by significant increases in Europe, America, Middle East Africa, and Asia Pacific regions [4][11]. - Domestic revenue slightly declined to RMB25.25 billion (YoY -0.31%), primarily due to a downturn in the central air conditioning industry, although the company maintains a strong market position with Hisense Hitachi [12]. Financial Performance Summary - Revenue projections for the next few years are as follows: RMB97.05 billion in 2025, RMB102.73 billion in 2026, and RMB112.62 billion in 2027, reflecting growth rates of 5%, 6%, and 10% respectively [2][10]. - Net profit is expected to grow from RMB3.69 billion in 2025 to RMB4.62 billion in 2027, with corresponding growth rates of 10%, 11%, and 13% [2][10]. - The company's gross profit margin is projected to improve slightly from 21.1% in 2025 to 21.4% in 2026 and remain stable thereafter [2][10]. Valuation - The report anticipates an EPS of RMB2.66 for 2025, RMB2.95 for 2026, and RMB3.34 for 2027, with a PE ratio of 13x for 2025 [6][13]. - The valuation reflects the company's ongoing global expansion and product optimization strategies under national subsidy policies, which are expected to enhance profitability [6][13].

Investment Rating - The report assigns an "Outperform" rating to several companies in the essential consumer goods sector, including Haidilao, Youran Dairy, Jiumaojiu, Modern Farming, Dasheng Holdings, Yihai International, Aoyou, and China Feihe, while Budweiser APAC is rated as "Neutral" [1]. Core Insights - The report highlights a general decline in spot cost indices for six categories of consumer goods, while futures indices primarily increased [38]. - The spot cost indices for dairy products, soft drinks, frozen foods, beer, instant noodles, and condiments changed by -2.92%, -2.46%, -1.88%, -1.78%, -1.58%, and -1.29%, respectively, while the futures cost indices changed by -1.52%/+1.64%/-1.77%/+3.57%/+0.84%/+2.89% [38]. Summary by Category Beer - The spot cost index decreased by 1.78% month-on-month, while the futures index increased by 3.57% [39]. - Year-to-date, the spot and futures indices have changed by -4.54% and -5.08%, respectively [39]. Seasonings - The spot cost index decreased by 1.29% month-on-month, while the futures index increased by 2.89% [40]. - Year-to-date, the spot and futures indices have changed by -1.7% and -3.2%, respectively [40]. Dairy Products - The spot cost index decreased by 2.92% month-on-month, and the futures index decreased by 1.52% [41]. - Year-to-date, the spot and futures indices have changed by -3.87% and -1.08%, respectively [41]. Instant Noodles - The spot cost index decreased by 1.58% month-on-month, while the futures index increased by 0.84% [42]. - Year-to-date, the spot and futures indices have changed by -4.43% and -3.07%, respectively [42]. Frozen Foods - The spot cost index decreased by 1.88% month-on-month, and the futures index decreased by 1.77% [43]. - Year-to-date, the spot and futures indices have changed by -2.95% and -3.6%, respectively [43]. Soft Drinks - The spot cost index decreased by 2.46% month-on-month, while the futures index increased by 1.64% [44]. - Year-to-date, the spot and futures indices have changed by -5.91% and -5%, respectively [44].

Group 1: Financial Performance - Borouge's Q2 2025 revenue reached $1.305 billion, exceeding market expectations of $1.214 billion[2] - The EBITDA margin for Q2 2025 was 34%, down from 41% in Q2 2024 and below the expected 37%[2] - Net profit for Q2 2025 was $192 million, lower than the consensus estimate of $199 million[6] Group 2: Dividend and Guidance - Borouge announced an interim dividend of 8.1 fils per share, consistent with previous guidance of 16.2 fils per share for FY 2025[1] - The company reaffirmed its dividend policy, committing to distribute $1.3 billion in dividends for FY 2025 until the completion of the Borouge Group International transaction[4] Group 3: Strategic Developments - ADNOC Group and OMV proposed a strategic merger of Borouge and Borealis, aiming for a combined nominal capacity of 13.6 million tons per year[3] - The new entity is expected to achieve approximately $7 billion in EBITDA over its lifecycle, with annual synergies of $500 million[3] Group 4: Market Position and Risks - Borouge maintains a cost leadership position in the global petrochemical industry, primarily due to the use of low-cost natural gas liquids[4] - Key risks include declining demand for petrochemical products, narrowing price spreads, and project execution risks[4]

政策连续，兼顾长短 [Table_Authors] 黄汝南(分析师) ——2025 年 7 月政治局会议点评 本报告导读： 政策依旧留有后手，密切关注外部风险可能的反复和国内基本面的变化，以及"十五 五"规划中确定性的产业线索。 投资要点： [Table_Summary] 中共中央政治局 7 月 30 日召开会议，决定 2025 年 10 月召开中共 四中全会，研究制定"十五五"规划的建议，并分析研究当前经济形 势和部署下半年经济工作。总的来看有三个特征：一是对内外部形 势的判断相较 4 月政治局会议更加积极；二是强调政策连续性，下 半年有望迎来"适时加力"的窗口期；三是适逢"十五五"规划起草在 即，政策兼顾短期稳增长和长期促改革。与 2020 年 7 月政治局会 议对"十四五"的相关表述相比，亮点是增加了"推动人的全面发展、 全体人民共同富裕迈出坚实步伐"的表述，这与此前强调的"投资于 人"一脉相承。 从对下半年工作的具体部署来看，有以下几个亮点： huangrunan@gtht.com 登记编号 S0880523080001 证 券 研 究 宏观研究 /[Table_Date] 2025.07.30 20 ...

Investment Rating - The report assigns an "Outperform" rating to Luckin Coffee, indicating an expected total return over the next 12-18 months that exceeds the relevant market benchmark by more than 10% [14]. Core Insights - Luckin Coffee reported a revenue of RMB 12.4 billion for Q2, representing a year-on-year growth of 47%. The adjusted net profit reached RMB 1.4 billion, up 44% year-on-year [5][2]. - The company continues to focus on market share and scale growth, with an average monthly transacting customer count of 91.7 million, a 32% increase year-on-year. The total number of stores reached 26,206, with a net increase of 2,109 stores quarter-on-quarter [5][1]. - The company is expanding its international presence, with new stores opening in Singapore and New York, marking a significant step in its internationalization strategy [1][2]. Financial Performance - Directly operated stores generated revenue of RMB 9.14 billion, a 46% increase year-on-year, with same-store sales growth of 13.4% [1][2]. - Franchise stores contributed RMB 2.87 billion in revenue, reflecting a 55% year-on-year increase, driven by significant growth in delivery fees due to participation in delivery platform subsidy activities [1][2]. - The adjusted operating profit was RMB 1.85 billion, a 61% increase year-on-year, with an adjusted operating profit margin of 15%, up 1.3 percentage points year-on-year [2][1]. Future Outlook - The company aims to continue expanding market share and maintain a high pace of store openings to capitalize on growing consumer demand, achieving rapid revenue growth [3][6]. - Luckin Coffee plans to leverage scale advantages and operational efficiency to offset the impact of delivery fee fluctuations, thereby sustaining relatively stable profitability [3][6].

Investment Rating - The report does not explicitly state an investment rating for MediaTek, but it highlights solid performance and growth potential in AI SoC and ASIC businesses, suggesting a positive outlook for the company. Core Insights - MediaTek reported 2Q25 revenue of NTD 150.4 billion, slightly below market consensus of NTD 151.2 billion, representing a 1.9% QoQ decrease and an 18.1% YoY increase. EPS reached NTD 17.5, exceeding market expectations. The gross margin was 49.1%, up 1 percentage point QoQ, aided by a one-off contribution from a long-term supply agreement [1][5][9]. - The ASIC business is a significant growth driver, with a total addressable market (TAM) exceeding USD 40 billion. MediaTek is expanding its ASIC R&D resources and expects substantial revenue contributions starting in 2026, with a target of reaching USD 1 billion in revenue by the end of 2026 [2][6][10]. - MediaTek is actively investing in 2nm process technology, with the first 2nm chip expected to tape out in September 2023, which will enhance performance and power efficiency for both SoC and ASIC businesses [3][7][10]. - Collaboration with NVIDIA continues to deepen, with the GB10 chip entering mass production in Q3, which is expected to contribute to revenue growth [4][8][10]. - For 3Q25, MediaTek expects revenue between NTD 130.1 billion and NTD 140 billion, a QoQ decrease of 7% to 13%, but a YoY increase of 10% to 18%. The gross margin is projected at 47% [9][10]. Summary by Sections Financial Performance - 2Q25 revenue: NTD 150.4 billion, -1.9% QoQ, +18.1% YoY [1][5] - EPS: NTD 17.5, exceeding expectations [1][5] - Gross margin: 49.1%, +1 ppt QoQ [1][5] ASIC Business - Strong performance in enterprise ASIC sector with TAM over USD 40 billion [2][6] - Rapid expansion of ASIC R&D resources [2][6] - Expected revenue contributions starting in 2026, targeting USD 1 billion by end of 2026 [2][6][10] 2nm Process Development - Active investment in 2nm process technology [3][7] - First 2nm chip expected to tape out in September 2023 [3][7] Collaboration with NVIDIA - Ongoing collaboration in chip business and automotive cockpit chips [4][8] - GB10 chip to enter mass production in Q3 [4][8] Future Guidance - 3Q25 revenue guidance: NTD 130.1 billion to NTD 140 billion [9][10] - Expected gross margin: 47% [9][10]